- Hengrui, Kailera's GLP-1 pill posts encouraging efficacy but high side effect rates in late-stage China trialsThe GLP-1 pill being developed by Hengrui Pharma and Kailera Therapeutics posted decent results in two late-stage China-based trials — one in obesity and the other in diabetes. But the safety pro…Endpoints · 19d ago↗ source
- STAT+: Compass says depression drug has long-lasting benefitsVertex makes its largest-ever deal, skyrocketing health insurance costs, and more biotech news from The ReadoutSTAT · 19d ago↗ source
- STAT+: America’s employer health insurance is decayingSTAT's Bob Herman examines the under-the-radar crisis brewing in employer-based health insurance.STAT